Bibliography
- Ogden CL, Carroll MD, McDowell MA, for the Division of Health and Nutrition Examination Surveys. Obesity among adults in the United States-no statistically significant change since 2003 – 2004. NCHS Data Brief. November 2007. US Dept of Health and Human Services. Centers for Disease Control and Prevention
- Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999 – 2008. JAMA 2010;303(3):235-41
- James PT, Rigby N, Leach R; for the International Obesity Task Force. The obesity epidemic metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil 2004;11:3-8
- World Health Organisation factsheet number 311 – obesity and overweight. Available from: www.who.int/mediacentre/factsheets/fs311/en/index.html
- Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 2002;236:554-9
- Marsk R, Freedman J, Tynelius P, Antiobesity surgery in Sweden from 1980 to 2005: a population-based study with a focus on mortality. Ann Surg 2008;248(5):777-81
- Kissebah AH, Freedman DS, Peiris AN. Health risks of obesity. Med Clin North Am 1989;73:111-38
- Mokdad AH, Marks JD, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA 2004;29(10):1238-45
- Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res 1998;6(2):97-106
- Wing RR. Long term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987;147:1749-53
- Sjostrom L, Lindroos AK, Peltonen M, Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-93
- Tuomilehto I, Lindstrom I, Eriksson JG, for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50
- Adams TD, Gress RE, Smith SC, Long-Term mortality after gastric bypass surgery. NEJM 2007;357(8):753-61
- Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071612.pdf
- Fujioka K, Lee MW. Pharmacologic treatment options for obesity: current and potential medications. Nutr Clin Pract 2007;22:50-4
- Padwal R, Li SK, Lau DC. Long term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2003;4:CD004094
- Cowen & Co. Therapeutic Categories Outlook- Obesity. March 2011
- Astrup A, Caterson I, Zelissen P, Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004;12:1658-9
- Bray GA, Hollander P, Klein S, A 6 month randomized, placebo-controlled, dose ranging trial of topiramate for weight loss in obesity. Obes Res 2003;11:722-33
- Wilding J, Van Gaal L, Rissanen A, A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 2004;28(11):1399-410
- Anderson JW, Greenway FL, Fujioka K, Buproprion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002;10:633-41
- Li Z, Maglione M, Tu W, Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532-46
- Greenway FL, Whitehouse MJ, Guttadauria M, Rational design of a combination medication for the treatment of obesity. Obesity 2009a;17:30-9
- Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci 2005;8:571-8
- Greenway FL, Dunayevich E, Tollefson G, Comparison of combined buproprion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 2009b;94:4898-906
- Orexigen press release. Available from: http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&ID=1308920&highlight
- Oommen KJ, Mathews S. Zonisamide, a new anti-epileptic drug. Clin Neuropharmacol 1999;22:192-200
- Gadde KM, Yonish G, Foust MS, Wagner HR. Combination therapy of Zonisamide and Buproprion for weight reduction in obese women: a preliminary randomized open label study. J Clin Psychiatry 2007;68:1226-9
- Fujioka K, Apovian C, Hill J. The evolution of obesity therapies: new applications for existing drugs. MedscapeCME Diabetes Endocrinology, 2010. Available from: http://cme.medscape.com/viewarticle/722366
- Myers MG, Leibel RL, Seeley RJ, Schwartz MW. Obesity and Leptin resistance: distinguishing cause from effect. Trends Endocrinol Metab 2010;10(11):643-51
- Lutz TA. Pancreatic Amylin as a centrally acting satiating hormone. Curr Drug Targets 2005;6:181-9
- Lutz TA. Amylinergic control of food intake. Physiol Behav 2006;89:465-71
- Hollander P, Maggs DG, Ruggles JA, Effect of Pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 2004;12:661-8
- Chan JL, Roth JD, Weyer C. It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development. J Investig Med 2009;57(17):777-83
- Ravussin E, Smith SR, Mitchell JA, Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity. Pharmacotherapy 2009;17(9):1736-43
- Amylin Pharmaceuticals press release. Amylin pharmaceuticals announces positive results from dose ranging clinical study of Pramlintide/Metreleptin combination treatment for obesity. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=101911&p=irol-newsArticle&ID=1305954
- Nichols DE. Hallucinogens. Pharmacol Ther 2004;101:131-8
- Fitzgerald LW, Burn TC, Brown BS, Possible role fo valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000;57:75-81
- Launay JM, Herve P, Peoc'h K, Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 2002;8:1129-35
- Kennett GA, Clifton PG. New Approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Pharmacol Biochem Behav 2010;97:63-83
- Smith SR, Weissman NJ, Anderson CM, NEJM 2010;363:245-56
- Arena Pharmaceuticals, Inc., Press Release. Arena Pharmaceuticals reports positive, highly significant BLOSSOM trial results for weight management; NDA submission on track for December. September 18th, 2009. Available from: http://invest.arenapharm.com/releasedetail.cfm?ReleaseID=410040 [Last accessed February 2011]
- Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007;59:151-84
- DeFronzo RA, Ratner RE, Han J, Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
- Astrup A, Rossner S, Van Gaal L, Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study. Lancet 2009;374(9701):1606-16
- Wadden T, Hollander P, Klein S, Liraglutide provides weight maintenance and additional weight loss after low-calorie diet-induced weight loss in obese subjects without diabetes: the SCALE™ maintenance study. Presented at the American Diabetes Association's 71st Scientific Sessions, 24 – 28 June 2011, San Diego, California, USA
- Kopelman P, DeGroot G, Rissanen A, A randomized, placebo-controlled, trial of Cetilistat (ATL-962), a novel lipase inhibitor and orlistat for the management of obese type 2 diabetic patients. Diabetes Metab 2006;55(Suppl 1):A395
- Sjodin Effect of Tesofensine on energy metabolism and appetite, I J of Obesity, 34, 2010 (1634-1643)(c NeuroSearch. "Tesofensine". Available from: http://www.neurosearch.dk/Default.aspx?ID=118 [Last accessed 17 February 2011]
- Astrup A, Madsbad S, Breum L, Effect of tesofensine on bodyweight loss, body composition and quality of life in obese patients: a randomized, double-blind placebo controlled trial. Lancet 2008b;372:1906-13
- Parker E, Van Heek M, Stamford A. Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status. Eur J Pharmacol 2002;440:173-87
- Shinogi press release. Shinogi announces positive top line efficacy results from year-long studies of Velneperit, a novel NPY Y5 receptor antagonist being investigated for the treatment of obesity. Available from: http://www.shionogi.co.jp/ir_en/news/detail/e_090217-2.pdf [Last accessed February 2011]
- Greenway RM, Schlossberg L, Dooley WC. Safety of obesity drugs. Expert Opin Drug Saf 2005;4:1083-95
- James WP, Caterson ID, Coutinho W, Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363(10):905-17
- Marcadia Biotech website. GIP/GLP-1 dual agonist. Available from: http://www.marcadiabiotech.com/development-programs/gipglp-1-dual-agonist.aspx [Last accessed 1 May 2011]
- Knowler WC, Barrett-Connor E, Fowler SE, Reduction in the incidence of type 2 diabetes with lifestyle intervention or Metformin. N Engl J Med 2002;346(6):393-403
- Sjostrom L, Narbro K, Sjostrom CD, Effect of bariatric surgery on mortality in Swedish Obese subjects. N Engl J Med 2007;357(8):741-52